BrainsWay

Contributing Author

Recent Articles by BrainsWay

4 hours	Landmark Data Validate BrainsWay's SWIFT Deep TMS, Beginning a New Era in Depression Treatment BWAY +6.21% GlobeNewswire
Feb-25	BrainsWay to Report Fourth Quarter and Full Year 2025 Financial Results on March 11, 2026 BWAY GlobeNewswire
Feb-23	BrainsWay to Participate in the Citi 2026 Unplugged MedTech and Life Sciences Access Day BWAY GlobeNewswire
Feb-19	BrainsWay Announces New Minority-Stake Investment in Canadian Provider, BrainStim Health Inc. BWAY -8.22% GlobeNewswire
Feb-18	BrainsWay Reports Cigna's Evernorth Behavioral Health to Eliminate Prior Authorization Requirements for TMS Coverage, Accelerating Access to Care BWAY GlobeNewswire
Feb-17	BrainsWay Announces Change in ADS-to-Ordinary Share Ratio BWAY +8.61% GlobeNewswire
Jan-21	BrainsWay Announces Draft Coverage Policy from Highmark for Accelerated Deep TMS BWAY GlobeNewswire
Jan-12	BrainsWay Announces FDA Approval of Neurolief's ProlivRx Neuromodulation System for Major Depressive Disorder (MDD) BWAY GlobeNewswire
Jan-07	BrainsWay Announces First Coverage Policy for Accelerated Deep TMS BWAY GlobeNewswire
Dec-22	BrainsWay Reports Expansion of Adolescent Depression Coverage Applicable to Deep TMS BWAY +10.05% GlobeNewswire
Nov-25	BrainsWay to Host Virtual Analyst & Investor Day to Discuss the Company's Growth Strategy and Deep TMS Treatment December 1, 2025 BWAY GlobeNewswire
Nov-17	BrainsWay Launches First Clinical Trial of Deep TMS 360 System for Alcohol Use Disorder BWAY GlobeNewswire
Nov-13	BrainsWay Receives FDA Clearance of Deep TMS as Adjunct Therapy for Major Depressive Disorder (MDD) in Adolescents Aged 15 to 21 BWAY GlobeNewswire
Nov-11	BrainsWay Reports Third Quarter 2025 Financial Results and Operational Highlights BWAY -5.83% GlobeNewswire
Nov-04	BrainsWay Reports National Institutes of Health Grant to Leading U.S. Research Team Investigating Accelerated Deep TMS for Treatment of Alcohol Use Disorder BWAY GlobeNewswire
Oct-28	BrainsWay to Report Third Quarter 2025 Financial Results on November 11, 2025 BWAY GlobeNewswire
Oct-27	BrainsWay Announces Additional Minority-Stake Investments in Leading U.S. Mental Health Providers BWAY GlobeNewswire
Sep-16	BrainsWay Receives FDA Clearance for Accelerated Deep TMS Protocol for Non-Invasive Treatment of Major Depressive Disorder (MDD) BWAY +11.89% GlobeNewswire
Aug-21	BrainsWay Targets Expansion of its Total Addressable Market through a Strategic Investment in Neuromodulation Systems Developer, Neurolief Ltd. BWAY GlobeNewswire
Aug-20	BrainsWay Acquires Minority-Stake in Axis Integrated Mental Health BWAY GlobeNewswire
Aug-13	BrainsWay Reports Second Quarter 2025 Financial Results and Operational Highlights BWAY GlobeNewswire
Jul-30	BrainsWay Champions TMS Education with Sponsorship of Two Free CME Courses for Mental Health Professionals BWAY GlobeNewswire
Jul-30	BrainsWay to Report Second Quarter 2025 Financial Results on August 13, 2025 BWAY GlobeNewswire
Jun-11	BrainsWay Reports Positive Results from Multicenter Randomized Study of Accelerated Deep TMS for Major Depressive Disorder (MDD) BWAY GlobeNewswire
Jun-10	BrainsWay Announces Gold Sponsorship at the 2025 Clinical TMS Society Annual Meeting in San Diego BWAY GlobeNewswire
Jun-04	BrainsWay Announces $5 Million Minority-Stake Investment in Stella MSO, LLC BWAY GlobeNewswire
May-13	BrainsWay Reports First Quarter 2025 Financial Results and Operational Highlights BWAY +11.10% GlobeNewswire
May-01	BrainsWay to Showcase Deep TMS at the 2025 American Psychiatric Association Annual Meeting in Los Angeles BWAY GlobeNewswire

BrainsWay

Recent Articles by BrainsWay

Upgrade your FINVIZ experience